Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

2018 Tecentriq (atezolizumab; Roche/Chugai) Drug Analysis: A Fully Humanized Monoclonal Antibody that Targets Programmed Death-Ligand 1 (PD-L1) - ResearchAndMarkets.com

Research and Markets
Posted on: 15 Feb 18

The "Drug Analysis: Tecentriq" drug pipelines has been added to ResearchAndMarkets.com's offering.

Tecentriq (atezolizumab; Roche/Chugai) is a fully humanized monoclonal antibody that targets programmed death-ligand 1 (PD-L1).

PD-L1 is expressed on the surface of antigen-presenting cells and some tumor cells. PD-L1 binds to programmed death-1 (PD-1) co-inhibitory receptors which are expressed on the surface of T cells after T-cell activation.

The receptor ligand interaction produces inhibitory signals which regulate T-cell activation and promote immune tolerance, which favors tumor progression. By blocking the PD-L1/PD-1 interaction, Tecentriq enables T-cell activation and allows the immune system to mount a more effective anti-tumor response.

Product Profiles

  1. Tecentriq: Prostate cancer
  2. Tecentriq: Colorectal cancer (CRC)
  3. Tecentriq: Ovarian cancer
  4. Tecentriq: Bladder cancer
  5. Tecentriq: Renal cell cancer (RCC)
  6. Tecentriq: Non-small cell lung cancer (NSCLC)
  7. atezolizumab: Breast cancer: triple-negative

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/4rj49c/2018_tecentriq?w=4

View source version on businesswire.com: http://www.businesswire.com/news/home/20180215005580/en/

Business Wire
www.businesswire.com

Last updated on: 15/02/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.